オキシコドン

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Warning

• 危険有害性情報

  H302：飲み込むと有害

  H336：眠気やめまいのおそれ

  H362：授乳中の子に害を及ぼすおそれ

• 注意書き

  P202：全ての安全注意を読み理解するまで取り扱わないこ と。

  P260：粉じん/煙/ガス/ミスト/蒸気/スプレーを吸入しないこ と。

  P263：妊娠中/授乳期中は接触を避けること。

  P264：取扱い後は皮膚をよく洗うこと。

  P264：取扱い後は手や顔をよく洗うこと。

  P301+P312：飲み込んだ場合：気分が悪い時は医師に連絡する こと。

  P308+P313：暴露または暴露の懸念がある場合：医師の診断/手当てを 受けること。

オキシコドン 化学特性,用途語,生産方法

• 効能

  麻薬性鎮痛薬, オピオイド受容体作動薬

• 説明

  Oxycodone (Item No. 15465) is an analytical reference material categorized as an opioid. Oxycodone is regulated as a Schedule II compound in the United States. This product is intended for research and forensic applications.

• 使用

  Analgesic (narcotic).

• 定義

  oxycodone: An opioid, C₁₈H₂₁N₂,similar in structure to codeine butwith a –OH group in codeine replacedby a carbonyl group. It is ananalgesic often used for the treatmentof chronic pain. It is also usedillegally and is a controlled substancein most countries.

• 生物学の機能

  Oxycodone is nearly 10 times as strong as codeine, with absorption equal to that of orally administered morphine. Neither hydromorphone nor oxycodone is approved for use in children, and hydromorphone is contraindicated in obstetrical analgesia and in asthmatics.

• 一般的な説明

  Oxycodone is synthesized from the natural opium alkaloidthebaine. Oxycodone is the 14 beta-hydroxyl version of hydrocodone.This additional functional group gives oxycodonegreater potency (1.5 times orally) than hydrocodone presumablyby increasing receptor affinity. The oral bioavailabilityof oxycodone is 65% to 87%. The metabolism of oxycodonefollows the similar pattern of opioid metabolism withN-demethylation, O-demethylation, and their glucuronides allidentified. Per the manufacturer, the analgesic effect of oxycodonecorrelates well with oxycodone plasma concentrations,not the minimal amount of oxymorphone formed, thusoxycodone is not assumed to be a prodrug. There are no largescalestudies of oxycodone used for analgesia in CYP2D6poor metabolizers that can confirm this.
  Oxycodone is marketed in combination with acetaminophen(Percocet), aspirin (Percodan), and ibuprofen(Combunox). It has been available for over 50 years as animmediate-release tablet, and in 1995 an extended-releasetablet was approved by the FDA (OxyContin). OxyContin ismanufactured in eight strengths from 10 to 160 mg, and thehigh-dose preparations quickly became attractive to drugabusers. The extended-release tablets are crushed and theninjected or snorted to give an immediate high. The DrugAbuse Warning Network (DAWN) is a public health surveillancesystem that monitors drug-related emergency roomvisits and drug-related deaths. In 1995, they estimated that598,542 emergency room visits involved the nonmedical useof a pharmaceutical (e.g., antidepressant, anxiolytic, stimulant).Of these ER visits, 160,363 visits were attributed toopiates with an estimated 42,810 involving oxycodone or anoxycodone combination. Methadone and hydrocodone/combinationswere estimated to be similar to oxycodone.

• 薬理学

  Oxycodone is a potent semisynthetic opioid that has been in use for many years. In addition to actions at the MOP receptor, it may also have analgesic effects mediated via the KOP receptor, resulting in incomplete crosstolerance with morphine. It has a good oral bioavailability, and its plasma concentrations are more predictable than those of morphine after oral administration. It is available in both long- and short-acting oral preparations and, more recently, in a parenteral formulation. Oral oxycodone is roughly 1.5 times more potent than oral morphine.

• 安全性プロファイル

  Poison by intraperitoneal route. Moderately toxic by subcutaneous route. When heated to decomposition it emits toxic fumes of NOx.

オキシコドン 上流と下流の製品情報

76-42-6, オキシコドン キーワード